Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial

Journal of Neurology

Volumn 253, Issue 10, 2006, Pages 1337-1341

  Wissel, Jörg ^a,b   Haydn, Tanja ^a   Müller, Jörg ^a   Brenneis, Christian ^a   Berger, Thomas ^a   Poewe, Werner ^a   Schelosky, Ludwig D ^c  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Kliniken Beelitz GmbH   (Germany)

^c Kantonsspital Muensterlingen   (Switzerland)

Author keywords

Central pain; Nabilone; Spasticity; Synthetic cannabinoid

Indexed keywords

NABILONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAILY LIFE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; FEMALE; HUMAN; LIMB WEAKNESS; LOW DRUG DOSE; MALE; MOTOR PERFORMANCE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SPASTICITY;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; MUSCLE SPASTICITY; PAIN; PAIN MEASUREMENT; RECURRENCE; TETRAHYDROCANNABINOL;

EID: 33750618230     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-0218-8     Document Type: Article

References (30)

1. Shakespeare DT, Boggild M, Young C (2003) Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst RevCD001332
2. Beard S, Hunn A, Wight J (2003) Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 7:iii, ix-iii, 111
3. Iversen L (2003) Cannabis and the brain. Brain 126:1252-1270
4. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di MV (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300-302
5. Diana G, Malloni M, Pieri M (2003) Effects of the synthetic cannabinoid nabilone on spatial learning and hippocampal neurotransmission. Pharmacol Biochem Behav 75:585-591
6. Rubin A, Lemberger L, Warrick P, Crabtree RE, Sullivan H, Rowe H, Obermeyer BD (1977) Physiologic disposition of nabilone, a cannabinol derivative, in man. Clin Pharmacol Ther 22:85-91
7. Ahmedzai S, Carlyle DL, Calder IT, Moran F (1983) Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 48:657-663
8. Ward A, Holmes B (1985) Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 30:127-144
9. Kurzthaler I, Bodner T, Kemmler G, Entner T, Wissel J, Berger T, Fleischhacker WW (2005) The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol 20:291-293
10. Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W (2000) Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 20:44-49
11. Maurer M, Henn V, Dittrich A, Hofmann A (1990) Delta-9- tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 240:1-4
12. Martyn CN, Illis LS, Thom J (1995) Nabilone in the treatment of multiple sclerosis. Lancet 345:579
13. Hamann W, di Vadi PP (1999) Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 353:560
14. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:1517-1526
15. Petro DJ, Ellenberger C Jr. (1981) Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 21:413S-416S
16. Meinck HM, Schonle PW, Conrad B (1989) Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 236:120-122
17. Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y (1996) The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 34:446-452
18. Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW (1987) Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 7:39-50
19. Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF (1994) Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 55:324-328
20. Kogel RW, Johnson PB, Chintam R, Robinson CJ, Nemchausky BA (1995) Treatment of Spasticity in Spinal Cord Injury with Dronabinol, a Tetrahydrocannabinol Derivative. Am J Ther 2:799-805
21. Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH (2002) Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58:1404-1407
22. Killestein J, Uitdehaag BM, Polman CH (2004) Cannabinoids in multiple sclerosis: do they have a therapeutic role? Drugs 64:1-11
23. Okie S (2005) Medical Marijuana and the Supreme Court. N Engl J Med 353:648-651
24. Pertwee RG (2002) Cannabinoids and multiple sclerosis. Pharmacol Ther 95:165-174
25. Consroe P (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534-551
26. Baker D, Pryce G, Giovannoni G, Thompson AJ (2003) The therapeutic potential of cannabis. Lancet Neurol 2:291-298
27. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611
28. Consroe P (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534-551
29. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323:13-16
30. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D (2004) Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 8:173-177